Machine Learning-Based Classification of Gliomas and Tumor Grades with SHAP-Guided Feature Interpretation.

Overview

1. Neurosurgery Department, Hamad Medical Corporation, Doha 3050, Qatar
2. Department of Electrical Engineering, Qatar University, Doha 2713, Qatar; (M.S.I.S.); (T.Z.R.)
3. College of Medicine, Qatar University, Doha 2713, Qatar; (A.H.); (M.M.)
4. Department of Biochemistry, University of Regina, Regina, SK S4S 0A2, Canada
5. Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha 2713, Qatar

Abstract

Background: Gliomas are among the most common and heterogeneous primary brain tumors, exhibiting substantial molecular and transcriptomic diversity that complicates diagnosis, grading, and treatment planning. Advances in artificial intelligence (AI), particularly machine learning (ML), offer powerful opportunities to analyze high-dimensional gene expression data and support precision oncology. Methods: This study proposes an interpretable ML framework to classify brain tumor subtypes—glioblastoma, astrocytoma, and oligodendroglioma—and to predict tumor grades (2, 3, and 4) using microarray-based gene expression data. The analysis was conducted on the REMBRANDT dataset, comprising 464 labeled samples (221 glioblastoma, 148 astrocytoma, 67 oligodendroglioma, and 28 controls) and 314 tumor samples for grade classification. Results: The ML models achieved high performance for disease classification, with accuracies of 99.6% (AUC 99.89%) for glioblastoma, 98.3% (AUC 99.83%) for astrocytoma, and 98.95% (AUC 100%) for oligodendroglioma. Tumor grade predictions also performed strongly, achieving 83.7% accuracy (AUC 88.2%) for grade II vs. III, 91.3% (AUC 94.8%) for grade II vs. IV, and 84.2% (AUC 90.8%) for grade III vs. IV. SHAP analysis identified key genes contributing to the model predictions (e.g., WIF1, STX6, RGS5, and ACTR2), and KEGG enrichment identified the candidate pathways involved in vesicular transport, metabolism, and immune signaling. Conclusion: Overall, our findings demonstrate that interpretable ML models can accurately differentiate glioma subtypes and grades, and SHAP analysis can help identify the strongest predictors of our models. These findings provide additional insights into the heterogeneous genetic and molecular landscape of brain gliomas and are intended to complement, not replace, conventional histopathological diagnosis.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

• geo:GSE108476, at NCBI GEO; found in “Data Availability Statement”

Data Availability Statement

The gene expression dataset analyzed in this study is publicly available in the Gene Expression Omnibus (GEO) under accession number GSE108476 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108476) (REMBRANDT dataset).

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 30 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 9 authors, 10 keywords, 9 MeSH terms, 2 funders, 53 references.

Cite

This paper

Al-Rumaihi, G., Sumon, M. S. I., Hassanein, A., Malluhi, M., Hossain, S. A., Raad, T. Z., Chowdhury, M. E. H., Razali, R., & Pedersen, S. (2026). Machine Learning-Based Classification of Gliomas and Tumor Grades with SHAP-Guided Feature Interpretation. Genes, 17(5), 511. https://doi.org/10.3390/genes17050511

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1186/s12967-026-08385-7

Dihydrotanshinone I as a novel signal transducer and activator of transcription 3 inhibitor for glioblastoma treatment.

Journal: Journal of translational medicine

In common: NCBI GEO GSE108476, other condition, cellular / molecular, 1 reference

[2] doi:10.3390/medicina62061169 [code]

Survival Outcomes and Machine Learning-Based Prediction of 12-Month Mortality in Glioblastoma Before and During the COVID-19 Pandemic: A SEER Population-Based Study.

Journal: Medicina (Kaunas, Lithuania)

In common: other condition, 3 references

[3] doi:10.1038/s41598-026-52528-1 [code]

Single-cell analysis reveals corticosteroid-associated impairment of tumor-infiltrating NK cells in glioblastoma patients.

Journal: Scientific reports

In common: genetics / omics, other condition, 2 references

[4] doi:10.1371/journal.pone.0351405 [code]

Unimodal vs. multimodal deep learning for non-invasive MGMT promoter methylation prediction in glioblastoma: A systematic evaluation on the BraTS 2021 dataset.

Journal: PloS one

In common: genetics / omics, other condition, 2 references

[5] doi:10.3390/ijms27167240

1-Piperidine Propionic Acid Inhibits PAR2/SerpinB3 Signaling and Reduces Glioblastoma Tumor Aggressiveness.

Journal: International journal of molecular sciences

In common: other condition, cellular / molecular, 2 references

[6] doi:10.1038/s41598-026-56920-9

Overexpression of miR-219 as a potential therapeutic strategy of glioblastoma cells in vitro.

Journal: Scientific reports

In common: other condition, cellular / molecular, 2 references

[7] doi:10.1186/s13293-026-00927-4 [code]

Gene regulatory network analysis identifies dysregulation of hypoxia pathways as contributing to glioblastoma treatment resistance in females.

Journal: Biology of sex differences

In common: other condition, cellular / molecular, 2 references

[8] doi:10.3390/diagnostics16152407

BG-YOLO11s: Boundary-Guided YOLO11 with Bézier Contour Augmentation for Brain Tumour Segmentation in T1-CE MRI.

Journal: Diagnostics (Basel, Switzerland)

In common: other condition, 2 references

[9] doi:10.1038/s41467-026-75882-0 [code]

A massively parallel CRISPR-based screening platform for modifiers of neuronal depolarization.

Journal: Nature communications

In common: cellular / molecular, 2 references

[10] doi:10.1371/journal.pone.0349101

Overexpression of key complement regulators in glioblastoma.

Journal: PloS one

In common: genetics / omics, other condition, cellular / molecular, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.